Renew Biotechnologies subsidiary Wasatch BioLabs (WBL), a US sequencing service provider focused on long-read sequencing, announced on Monday the addition of three Oxford Nanopore-developed research-use-only (RUO) assays to its service portfolio: a Pharmacogenomics (PgX) panel, Telomere Sequencing, and mRNA Vaccine Quality Control.

Headquartered in a 20,000 sq ft CLIA-registered laboratory, WBL combines Oxford Nanopore's assays with its expertise in long-read sequencing to deliver data at scale.

Pharmacogenomics (PGx) Panel (PGxpanel) delivers full-gene coverage -- including repeats, structural variants, and hybrid alleles that are often missed by short-read methods. Oxford Nanopore's telomere workflow provides molecule-level resolution of telomere length distributions and subtelomeric methylation across individual chromosome arms.

With long reads, single-molecule resolution, and no amplification artifacts, Wasatch BioLab's mRNA Vaccine QC service delivers a complete and accurate view of mRNA constructs, from early development through lot release and stability studies, all within a single streamlined workflow. This approach preserves critical features such as poly(A) tails, structural heterogeneity, and overall integrity to confirm product quality and support regulatory-ready development.

Together, these assays expand WBL's ability to support biopharma and biotech teams across a wide spectrum of applications -- from drug response studies, to telomere biology research, to mRNA vaccine development. With Oxford Nanopore's assays run through WBL's high-capacity infrastructure and expert bioinformatics pipelines, researchers gain access to advanced long-read workflows in a setting designed for both discovery and translational impact, WBL said.